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Current treatment options for allergic rhinitis (AR) include allergen avoidance and environmental control, pharmacotherapy, nasal 
surgery and immunotherapy. Among these, immunotherapy is the only therapeutic option that modifies fundamental immunologic 
mechanism by inducing desensitization. Specific allergen immunotherapy has been used for 1 century since 1911 and subcutaneous 
immunotherapy (SCIT) has been demonstrated to be effective in asthma and AR. However, SCIT has several disadvantages such as 
inconvenience, invasiveness and potentially severe systemic reactions. Thus, sublingual immunotherapy (SLIT) has recently received 
much attention around the world as a treatment for AR and is now widely used to replace the subcutaneous route. SLIT has recently 
been introduced in Korea and is now available for AR treatment in the Asia-Pacific region. This review offers better understanding of 
SLIT for AR by summarizing published articles and our previous works regarding proposed mechanisms, indication and efficacy, safety 
and adverse events, and compliance.
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INTRODUCTION
The incidence of allergic rhinitis (AR) in the general population 
is currently around 10%-25%. Medical cost for AR treatment is 
increasing, and considering comorbid diseases including asthma, 
the treatment of AR has become more than just treating the 
rhinitis itself  [1]. AR treatment can be classified into 4 categories: 
(1) avoidance and environmental control, (2) pharmacotherapy, 
(3) surgical treatment and (4) immunotherapy. Avoidance and 
environmental control is the safest way, but these are not always 
feasible. Intranasal corticosteroids and oral antihistamines have 
been accepted to be effective with few adverse effects. However, 
medical therapy only reduces allergic symptoms rather than 
reversing basic immunologic profiles of the AR patients. Surgical 
treatment is usually performed to correct structural problems 
which can aggravate nasal allergic symptoms and reduce the 
effective delivery of intranasal corticosteroids. 
Allergen specific immunotherapy (SIT) has been studied and 
used for 1 century since Noon’s first report in 1911 [2]. SIT is 
the only treatment option that modified fundamental allergic 
mechanism by inducing desensitization. At first, SIT was used for 
allergic diseases caused by pollen allergen, such as hay fever or 
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seasonal AR, however today, indications extends to hymenoptera 
venom, house dust mites (HDMs), animal dander and allergic 
diseases for fungi [3]. Allergen extracts are injected intradermally. 
For safety, dosage starts at low concentration and increases slowly. 
When dosage reaches to maintenance concentration, maintenance 
dose is injected regularly for 3-5 years.
However, subcutaneous immunotherapy (SCIT) has several 
disadvantages. Patients have to visit clinicians’ office regularly 
for injection and to tolerate the injection pain, and doctors 
should concern side effect such as anaphylaxis. Thus, SCIT is 
recommended to be performed only in facilities with adequate 
personnel and equipment that can effectively handle anaphylactic 
events [4]. Because of these inconveniences, other allergen 
administration methods including intranasal, oral, sublingual routes 
have been developed. Among them, sublingual immunotherapy 
(SLIT) has been widely used in European countries replacing SCIT 
because SLIT has several advantages: noninvasiveness, home 
administration, less frequency of severe adverse reaction than SCIT. 
The efficacy and safety of SLIT have been studied and in 2008, 
British Society for Allergy and Clinical Immunology announced 
SLIT as safe immunotherapy for AR and asthma [5] and in 2009, 
World Allergy Organization Position Paper about SLIT described 
its efficacy and safety [6]. This article discussed the proposed 
mechanism, indication, efficacy according to allergen, safety and 
compliance of SLIT.
Proposed mechanisms of SLIT
There are several studies that reported the immunologic 
changes of SLIT were similar to those of SCIT [7]. Both SLIT and 
SCIT are allergen specific immunotherapy, which derive 3 major 
immunologic changes: (1) regulation of allergen specific antibody 
response, (2) reduction of proinflammatory cell recruitment and 
activation, and (3) changes in allergen specific T cell response. In 
addition, we discuss about the oral (mucosal) tolerance as well as 
the 3 above-mentioned mechanisms.
(1) Regulation of allergen specific antibody response
It is typical characteristics of allergic disease that serum allergen 
specific IgE binds to FcεRI receptor on mast cell surface. Serum IgE 
level elevates in early phase of SCIT, but decreases several months 
after SCIT. This decline prevents seasonal rise of IgE in grass pollen 
allergic patients. However, early symptomatic improvement after 
immunotherapy does not relate to IgE level change because this 
change occurs in later phase of immunotherapy. Allergen specific 
IgG (mostly IgG1 and IgG4) rises, which relates to the clinical 
improvement. Also, IgA level sometimes increases [7]. 
In SLIT, similar to SCIT, the increase of allergen specific IgG4 level 
and the decrease of IgE/IgG4 ratio were observed. Recent meta-
analysis reported that SLIT provoked significant change of allergen 
specific IgG and IgG4 level [8] and one another meta-analysis 
did that allergen specific IgG4 level increased and change in IgE/
IgG4 ratio related to the reduction of skin reaction to allergen 
in later phase of SLIT and clinical improvement [9]. IgG4, known 
as blocking antibody, could antagonize and prohibit the allergic 
inflammation cascade resulting from antigen recognition by IgE. 
Therefore, the shift from IgE to IgG4 and change of IgE/IgG4 
ratio is important for successes of immunotherapy [10]. Allergen 
specific IgE level changes were controversial [11-13]. The 2-year 
HDM SLIT treatment in asthmatic children did not show any 
differences in HDM-specific IgE between SLIT and placebo groups 
[11]. In our study on AR patients, specific IgE for Dermatophagoides 
farinae increased after 12-month SLIT, while specific IgE for 
Dermatophagoides pteronyssinus did not change significantly [12]. 
However, in grass pollen SLIT, time- and dose-dependent increases 
of Phleum pratense-specific serum IgE were found, indicating that 
the SLIT treatment had a significant allergen-specific effect on the 
immune system [13]. The change of IgA has also been reported. 
Antigen specific serum IgA rose in dose-dependent manner in SLIT 
with grass pollen allergen [13] and was up-regulated in SLIT with 
HDM allergen [14]. Thus, allergen specific IgG (and IgA) without 
any changes of IgE are thought to contribute to the clinical 
responses of SLIT.
(2) Reduction of proinflammatory cell recruitment and 
activation
SCIT reduces recruitment and activation of proinflammatory cells 
in mucosa related to allergic reaction. Recruitment and activation 
of mast cell, eosinophil and basophil decrease in the skin, the nasal 
cavity, the conjunctiva and the bronchial mucosa after allergen 
exposure when SCIT has been successful. SCIT induces peripheral 
T cell immune tolerance and regulates activation threshold of 
mast cell and basophil. Also, SCIT increases IL-10 production, which 
prohibits secretion of proinflammatory cytokines by mast cell, 
down-regulates functions and activities of eosinophil, and inhibits 
IL-5 production by Th0 and Th2 cells. Resembling these responses, 
SLIT decreased the level of basophil in the conjunctiva or the nasal 
cavity after allergen exposure. It was reported that the local or 
systemic eosinophil cationic protein (ECP) level was decreased in apallergy.org
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SLIT for grass pollen [15] and HDMs [12]. 
(3) Changes in allergen specific T cell response
The balance between Th1 and Th2 responses is crucial for 
allergic inflammation. SCIT induces Th1 response and reduces 
synthesis of Th2 cytokines. In grass pollen SCIT, the shift from 
Th2 profile to Th1 profile occurred in nasal mucosa or skin 
consistently although systemic change were not consistent. This 
results showed immunologic change is important not only in the 
peripheral blood but also in target organs. 
It is the key step of SIT to maintain immunologic tolerance of 
peripheral T cell by antigen specific regulatory T cell. SCIT induces 
regulatory T cell, which secretes IL-10 and TGF-β [7, 16, 17]. IL-10 has 
several immunoregulatory functions on Th1 and Th2 responses. IL-
10 promotes IgG4 rather than IgE class switching, and decreases 
MHC class II expression and activation and migration of mast 
cell and eosinophil [18]. TGF-β suppresses on both Th1 and Th2 
responses, contributes to generate regulatory T cell subsets and 
induces B-cell immunoglobulin class switching to IgA [19]. 
T cell response in SLIT has not been fully elucidated. Some 
reported that SLIT with grass pollen did not have significant 
effect on T cell function including cytokine synthesis and cell 
proliferation and did not raise the counts of dendritic cell and 
T cell in epithelium and lamina propria [20, 21]. However, other 
studies using HDM SLIT, showed SLIT reduces IL-13, one of the 
Th2 cytokines, peripheral monocyte proliferation, ECP and 
prolactin [22, 23] and induces IL-10 production [24]. The reduction 
of prolactin level could reflect that T cell activity was reduced 
because prolactin is produced by activated T cell. 
(4) Induction of oral mucosal immune tolerance
During SLIT, allergens are captured through FcεRI and/or 
other structures expressed by oral mucosal Langerhans-like DCs. 
DCs induce protolerogenic mechanisms in oral mucosa by the 
upregulation of coinhibitory molecule expression (B7H1 and B7H3) 
or release of IL-10 [25]. Allergen uptake of DCs attenuates their 
maturation and expression of chemokine receptor 7 (CCR7), being 
essential for the recruitment of DCs to peripheral lymphoid organs. 
Attenuated maturation and lower CCR7 expression of DCs after 
allergen uptake during migration to the lymphoid tissue might 
provide evidence of antigen presentation of DCs to T cells being 
performed outside local draining lymphoid tissues, ie, local contact 
of oral DCs with T cells in the oral mucosa [25]. Oral DCs are able 
to prime regulatory T (Treg) cells such as CD4
+ CD25
+ Foxp3
+ Treg 
cells, which increase in the oral epithelium during SLIT. Moreover, 
enhancement of Foxp3
+ Treg cells and IgG4 in peripheral blood as 
well as IL-10, IL-18 and signaling lymphocytic activation molecule 
in peripheral blood mononuclear cells was observed during SLIT 
[26, 27]. In addition, expression of programmed cell death ligand 
1 on monocytes and B cells increased, while IL-4 production 
decreased in patients receiving pollen SLIT [28].
Indications of SLIT
In 2008, Allergic Rhinitis and its Impact on Asthma (ARIA) [29] 
suggested the indications for SLIT: (1) carefully selected patients 
with rhinitis, conjunctivitis and/or asthma caused by pollen and 
mite allergy, (2) patients insufficiently controlled by conventional 
pharmacotherapy, (3) patients who have presented with systemic 
reactions during injection-specific immunotherapy, and (4) 
patients showing poor compliance with or refusing injections. 
SIT could apply to AR if the existence of allergen specific 
antibody and provocation of symptoms by the same allergen are 
proved [30]. To identify specific antigen, skin prick test (SPT) is 
preferred rather than multiple allergen simultaneous test which 
has lower sensitivity than SPT. Positive SPT result usually reflects 
the presence of antigen specific serum IgE, however, it should be 
correlated with clinical symptoms or AR history of the patients.
Some conditions relating patients’ characteristics as well 
as AR itself should be considered. Poor compliance and bad 
communication would make it hard to evaluate symptom, efficacy 
and side effects of SLIT. One study reported that SLIT in very young 
children aged 1 to 3 years was safe [31], which suggests that age 
limitation does not seem to exist.
Efficacy of SLIT
Meta-analysis have proved SLIT had therapeutic efficacy for 
asthma and both adult and childhood AR [8, 9, 32-34], and the 
ARIA group acknowledged the efficacy of SLIT on rhinitis patients 
for birch, cypress, grass, olive, Parietaria and HDM in 2008 [29].
There are some initial studies that SLIT did not have desensitizing 
effect to HDM and grass pollen allergen comparing to placebo 
group [35, 36]. Moreover, SLIT had therapeutic efficacy on only 
severe AR and at least 3 year-treatment was required for clinical 
improvement [35]. As time goes, several studies for confirming 
SLIT efficacy have been conducted. One double-blind placebo-
controlled (DBPC) studies including 855 patients with grass pollen 
AR showed moderate reduction of symptom score (16%) and 
medication use (28%) after 18-week treatment [37]. A recent meta-apallergy.org
Han DH, et al.
Asia Pacific
allergy
http://dx.doi.org/10.5415/apallergy.2011.1.3.123 126
analysis showed that the patient with SLIT had less symptom 
(SMD, −0.49) and medication scores (SMD, −0.32) [8]. In our study 
of HDM SLIT in 88 patient with AR, all symptoms including nasal, 
eye discomfort and sleep disturbance were significantly improved 
12 months after SLIT (p < 0.05) and a significant reduction of 
symptomatic medication use was observed between the first and 
12 months (p < 0.001) [12].
The efficacy of SLIT in children has shown controversies. A 
study reported low dose allergen administration for 2 years to 
asthmatic children with HDM allergy did not change immunologic 
parameters [11]. In 2006, one meta-analysis for confirming 
efficacy of SLIT for pediatric AR patients 3 to 18 years of age 
showed a significant reduction in both symptoms (SMD, 0.56) and 
medication use (SMD, 0.76) after SLIT [38]. Recently, World Allergy 
Organization Position Paper reported that SLIT for pollen and HDM 
had the efficacy in children with AR ≥5 years of age and might be 
safely used in children ≥3 years of age [6].
The maintaining effects after discontinuation of SLIT has not 
yet been fully established although those of SCIT has been 
acknowledged [39]. A study including 137 patients with HDM 
AR showed that a greater improvement in the 3 years of SLIT 
compared with the 2 years of SLIT [40]. In another study with 15 
years observation including mono-sensitized patients to HDM, 
clinical benefits of SLIT persisted for 7 years in patients with 3-year 
SLIT and for 8 years in those with 4, 5-year SLIT [41]. This study 
suggested that a 4-year SLIT is the optimal choice in present 
conditions because it induces a long-lasting clinical improvement 
similar to that of 5-year course and greater than that of a 3-year 
SLIT. 
Preventive effect for asthma of SLIT has been established. In 
a study including 113 children with hay fever limited to grass 
pollen, development of asthma was 3.8 times less frequent in the 
SLIT group than in the control group after 3-year treatment [42]. 
Another study reported that 35 patients with allergic asthma/
rhinitis due to HDM underwent SLIT for 4-5 years had significantly 
lower presence of asthma and use of antiasthmatic medication 
after SLIT, whereas 25 received only drug therapy had no change 
[43]. It also has been insisted that SLIT could prevent new allergen 
sensitization. One study reported that new sensitization appeared 
in 3.1% of 3-year SLIT patients although it appeared in 34.8% of 
patients who received drugs alone for 3 years [44].
Safety and adverse events
One of the advantages of SLIT over SCIT is the favorable safety 
profile. It is the safety that the most important advantage of SLIT 
comparing to SCIT. SCIT sometimes induces severe adverse side 
effects such as anaphylaxis. One DBPC study using grass and birch 
allergen reported 3.3% of patients received grass allergen and 
0.7% of patients received birch allergen had systemic side effect 
[45]. Postmarketing surveillance study showed 0.9% of injection, 
3.7% of patients underwent SCIT had systemic side effects [46]. 
According to a comprehensive review of published DBPC 
study, the adverse event rates were 23% in SLIT group and 12% 
in placebo group, and systemic events were 17% and 12%, 
respectively. Adverse event occurrences were not dose dependent 
and severe systemic reactions were not reported [47]. However, 
one DBPC study reported treatment related adverse events, 
irritation of the throat, and itching sensations in the mouth and 
ears, increased with dose [48]. There was no fatal event according 
to the report evaluating 66 studies including 4,378 patients, 
1,181,654 administrations [49]. Forty one of 66 studies reporting 
adverse events showed 1,047 adverse events during 386,149 
administrations (2.7/1,000 administration). Recent meta-analysis 
showed local reaction such as labial, buccolingual edema, buccal 
pruritus or throat irritation, and systemic reactions in the upper 
respiratory tract and associated organs (rhinitis, conjunctivitis or 
rhinoconjunctivitis) were more frequent in the SLIT group than in 
placebo group, however, asthma or wheeze occurred in similar 
rates in both SLIT and placebo groups and there was no fatality. 
Gastrointestinal problems were more common in SLIT group, 
especially children [8].
There were no mortality cases. Six cases with anaphylaxis, 
including 2 cases after using a mixture of multiple allergens, have 
been reported [50, 51]. One occurred in the treatment with latex 
rush protocol [52] and one developed after taking a dose 6-times 
(60 drops instead of 10 drops) greater than prescribed for HDM SLIT 
[53]. The remaining 2 occurred in the patients who had previously 
stopped SCIT due to severe systemic side effects [54]; a 13-year-old 
boy showed swelling of the tongue, angioedema of the eyes and 
generalized urticaria and a 27-year-old female experienced asthma 
symptoms, generalized itching and faintness with and abdominal 
cramps.
In our study, the incidence of adverse effects of SLIT was 52.1% 
(48 of 92 patients) during first 30 days, up-dosing phase [55]. 
Aggravation of AR symptoms was the most common adverse 
events during this phase. After 6 months or more, 13 patients 
(14.1%) experienced temporary adverse events such aggravation 
of symptoms, itching sensation in the oral cavity/lips/eyes/skin, apallergy.org
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gastrointestinal symptoms and breathing discomfort. However, 
these adverse events subsided spontaneously without medication. 
None of the patients needed to visit an emergency room.
Safety of SLIT in younger children has been studied. One study 
involving 65 children aged 3-7 years showed that side effects 
including urticaria, oral pruritus and gastrointestinal problem 
in children younger than 5 years were not severer than those 
in children aged 5-7 years [56]. Another study on 126 pediatric 
patients, aged 3-5 years, confirmed that SLIT is also safe in children 
under the age of 5 years [57]. Nine side effects in 7 children (5.6% 
patients and 0.2/1,000 doses) were reported and all side effects 
occurred during up-dosing phase: 6 gastrointestinal side effects, 2 
oral itching and 1 mild abdominal pain. All problems were solved 
by reducing dosage. The other study showed multiple allergen 
SLIT in children did not have more risk of adverse reaction than 
mono-allergen SLIT [58].
Compliance of SLIT
Compliance is critical problem for continuing SLIT because 
patients administer allergen by themselves or their parents. The 
drop-out rates which conducted in European countries were 5%-
30% in treated subjects [59-62]. In Korea, the drop-out rate of our 
series for 6 months were 31%, which was relatively high [55]. The 
most common reason of drop-out was inability to take medication 
according to schedule. Thus, convenient allergen formula and 
application schedule needs to be developed, and proper and 
prudent management of the patients is needed to reduce the 
drop-out rate.
CONCLUSION
SLIT has been establishing its role for AR. SLIT could be adopted 
for both adult and children patients with AR for pollen or HDM 
with safety. Long-term use of SLIT could change immunologic 
profiles. SLIT as well as SCIT does not make only clinical symptom 
improve but also prevents poly-sensitization and development of 
asthma. Also, risk of severe or fatal adverse events seemed to be 
much less than SCIT. 
However, there are still many unsolved problem. The duration 
and optimal dosage of SLIT are not well established. The effect 
duration after discontinuance of SLIT should be investigated more. 
The effect of SLIT in poly-sensitized patients and appropriate dose 
interval are still uncertain. Also, many of studies about SLIT have 
been conducted in European countries for Caucasian patients. 
Thus, further SLIT studies in Asia-Pacific region are needed.
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